{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:27:11Z","timestamp":1792160831118,"version":"4.4.0"},"reference-count":70,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T00:00:00Z","timestamp":1600473600000},"content-version":"vor","delay-in-days":39,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["asbmr.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The cardiovascular safety of denosumab has not yet been evaluated in a systematic review. This systematic review and meta-analysis sought to quantify the number of randomized controlled trials (RCTs) of denosumab (against comparators) reporting cardiovascular adverse events (CAEs) and examine the balance of CAEs between treatment arms. MEDLINE, Embase, and clinicaltrials.gov were searched from inception to October 26, 2019, for RCTs of denosumab versus comparators for any indication. Included trials were randomized, enrolled \u2265100 participants, and reported bone-related outcomes. Primary outcome for analysis was all CAEs, a composite endpoint representing summation of all CAEs as reported by included trials. Secondary outcomes included major adverse cardiovascular events (MACE). Data were pooled using a fixed effects model to determine relative risk (RR) and 95% confidence interval (95% CI). Risk of bias was assessed using the Cochrane risk-of-bias tool. Of 554 records screened, 49 were included, while 36 reported CAEs. Twenty-seven included trials (12 eligible for meta-analysis) were conducted in 13,202 postmenopausal women. Compared with bisphosphonates, there was a 46% (95% CI 1.05 to 2.02) increase in CAEs (85\/2136 events in denosumab-treated versus 58\/2131 events in bisphosphonate-treated; seven trials). There was a similar imbalance in a five-point (stroke, myocardial infarction, cardiovascular death, heart failure, atrial fibrillation) MACE endpoint (28\/2053 versus 12\/2050; RR = 2.33 [1.19 to 4.56]). Compared with placebo-treated women, there was no imbalance in total CAEs (439\/4725 events in denosumab versus 399\/4467 in placebo; RR = 0.79 [0.41 to 1.52]; seven trials). No imbalance in total AEs (versus bisphosphonates: 0.98 [0.92 to 1.04]; versus placebo: 0.99 [0.98 to 1.01]) occurred. Other indications showed no statistically significant results. The excess CAEs in postmenopausal women treated with denosumab compared with bisphosphonates, but not placebo, indirectly supports claims that bisphosphonates may suppress CAEs. Future trials should use standardized CAE reporting to better describe cardiovascular effects of bone active medications. (PROSPERO: CRD42019135414.) \u00a9 2020 American Society for Bone and Mineral Research (ASBMR).<\/jats:p>","DOI":"10.1002\/jbmr.4157","type":"journal-article","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T23:13:44Z","timestamp":1597187624000},"page":"24-40","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Cardiovascular Safety of Denosumab Across Multiple Indications: A Systematic Review and Meta-Analysis of Randomized Trials"],"prefix":"10.1093","volume":"36","author":[{"given":"Alexander H","family":"Seeto","sequence":"first","affiliation":[{"name":"School of Medicine Griffith University Gold Coast Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2730-6080","authenticated-orcid":false,"given":"Bo","family":"Abrahamsen","sequence":"additional","affiliation":[{"name":"Department of Medicine HolbaekHospital Holbaek Denmark"},{"name":"Musculoskeletal Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences University of Oxford Oxford UK"},{"name":"OPEN-Odense Patient Data Explorative Network Institute of Clinical Research, University of Southern Denmark Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2921-3742","authenticated-orcid":false,"given":"Peter R","family":"Ebeling","sequence":"additional","affiliation":[{"name":"Australian Institute for Musculoskeletal Science St Albans Australia"},{"name":"Bone and Muscle Health Research Group, Department of Medicine School of Clinical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Monash Medical Centre Clayton Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2955-0642","authenticated-orcid":false,"given":"Alexander J","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Disorders of Mineralisation Research Group, School of Medical and Health Sciences Edith Cowan University Joondalup Australia"},{"name":"Bone and Muscle Health Research Group, Department of Medicine School of Clinical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Monash Medical Centre Clayton Australia"},{"name":"OPEN-Odense Patient Data Explorative Network Institute of Clinical Research, University of Southern Denmark Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,11]]},"reference":[{"issue":"6","key":"2024012713535724800_jbmr4157-bib-0001","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/aje\/kwh080","article-title":"Metacarpal cortical area and risk of coronary heart disease: the Framingham study","volume":"159","author":"Samelson","year":"2004","journal-title":"Am J Epidemiol."},{"issue":"8763","key":"2024012713535724800_jbmr4157-bib-0002","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0140-6736(91)90489-C","article-title":"Non-trauma mortality in elderly women with low bone mineral density","volume":"338","author":"Browner","year":"1991","journal-title":"Lancet."},{"issue":"1","key":"2024012713535724800_jbmr4157-bib-0003","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00198-012-2213-5","article-title":"Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study","volume":"24","author":"Kang","year":"2013","journal-title":"Osteoporos Int."},{"issue":"1","key":"2024012713535724800_jbmr4157-bib-0004","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jbmr.3860","article-title":"Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women","volume":"35","author":"Reid","year":"2020","journal-title":"J Bone Miner Res"},{"key":"2024012713535724800_jbmr4157-bib-0005","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.atherosclerosis.2016.06.039","article-title":"Bisphosphonates for cardiovascular risk reduction: a systematic review and meta-analysis","volume":"252","author":"Kranenburg","year":"2016","journal-title":"Atherosclerosis."},{"issue":"15","key":"2024012713535724800_jbmr4157-bib-0006","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med."},{"issue":"9","key":"2024012713535724800_jbmr4157-bib-0007","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1210\/jc.2017-02163","article-title":"A phase III randomized placebo-controlled trial to evaluate efficacy and safety of Romosozumab in men with osteoporosis","volume":"103","author":"Lewiecki","year":"2018","journal-title":"J Clin Endocrinol Metabol."},{"issue":"16","key":"2024012713535724800_jbmr4157-bib-0008","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med."},{"issue":"8","key":"2024012713535724800_jbmr4157-bib-0009","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med."},{"issue":"3","key":"2024012713535724800_jbmr4157-bib-0010","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/jbmr.3019","article-title":"Comparative safety and effectiveness of denosumab versus zoledronic acid in patients with osteoporosis: a cohort study","volume":"32","author":"Choi","year":"2017","journal-title":"J Bone Miner Res."},{"key":"2024012713535724800_jbmr4157-bib-0011","doi-asserted-by":"crossref","first-page":"115121","DOI":"10.1016\/j.bone.2019.115121","article-title":"Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: systematic review and meta-analysis","volume":"130","author":"Lv","year":"2020","journal-title":"Bone"},{"issue":"1","key":"2024012713535724800_jbmr4157-bib-0012","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11657-019-0672-4","article-title":"No impact of anti-rank ligand and PTH analogs on cardiovascular risk in postmenopausal osteoporosis: a systematic literature review and meta-analysis","volume":"15","author":"Ferrieres","year":"2020","journal-title":"Arch Osteoporos"},{"issue":"8","key":"2024012713535724800_jbmr4157-bib-0013","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"issue":"7","key":"2024012713535724800_jbmr4157-bib-0014","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"2024012713535724800_jbmr4157-bib-0015","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ."},{"issue":"10","key":"2024012713535724800_jbmr4157-bib-0016","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol."},{"key":"2024012713535724800_jbmr4157-bib-0017","author":"GlaxoSmithKline"},{"issue":"7","key":"2024012713535724800_jbmr4157-bib-0018","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10\u2009years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9768","key":"2024012713535724800_jbmr4157-bib-0019","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"9","key":"2024012713535724800_jbmr4157-bib-0020","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"2024012713535724800_jbmr4157-bib-0021","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00520-013-2022-1","article-title":"Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors","volume":"22","author":"Henry","year":"2014","journal-title":"Support Care Cancer."},{"issue":"Suppl 1","key":"2024012713535724800_jbmr4157-bib-0022","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.3816\/CBC.2007.s.002","article-title":"Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer","volume":"7","author":"Lipton","year":"2007","journal-title":"Clin Breast Cancer."},{"key":"2024012713535724800_jbmr4157-bib-0023","author":"GlaxoSmithKline, Amgen"},{"issue":"3","key":"2024012713535724800_jbmr4157-bib-0024","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol."},{"issue":"2","key":"2024012713535724800_jbmr4157-bib-0025","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdu519","volume":"26","author":"Smith MR, Coleman RE, Klotz L","year":"2015","journal-title":"Ann Oncol"},{"issue":"35","key":"2024012713535724800_jbmr4157-bib-0026","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol."},{"issue":"23","key":"2024012713535724800_jbmr4157-bib-0027","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.2106\/JBJS.K.00774","article-title":"Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial","volume":"94","author":"Adami","year":"2012","journal-title":"J Bone Joint Surg Am"},{"issue":"6","key":"2024012713535724800_jbmr4157-bib-0028","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1210\/jc.2010-2784","article-title":"Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk","volume":"96","author":"Boonen","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2024012713535724800_jbmr4157-bib-0029","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/jbmr.251","article-title":"Effects of denosumab on bone turnover markers in postmenopausal osteoporosis","volume":"26","author":"Eastell","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024012713535724800_jbmr4157-bib-0030","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/jbmr.2043","article-title":"RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk","volume":"29","author":"Samelson","year":"2014","journal-title":"J Bone Miner Res."},{"issue":"12","key":"2024012713535724800_jbmr4157-bib-0031","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1359\/jbmr.070809","article-title":"Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD","volume":"22","author":"Lewiecki","year":"2007","journal-title":"J Bone Miner Res."},{"issue":"2","key":"2024012713535724800_jbmr4157-bib-0032","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone."},{"issue":"2","key":"2024012713535724800_jbmr4157-bib-0033","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1210\/jc.2010-1805","article-title":"Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial","volume":"96","author":"Miller","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2024012713535724800_jbmr4157-bib-0034","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00198-012-2052-4","article-title":"Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial","volume":"24","author":"McClung","year":"2013","journal-title":"Osteoporos Int."},{"issue":"6","key":"2024012713535724800_jbmr4157-bib-0035","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2024012713535724800_jbmr4157-bib-0036","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2024012713535724800_jbmr4157-bib-0037","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J Bone Miner Res."},{"issue":"7","key":"2024012713535724800_jbmr4157-bib-0038","first-page":"1953","article-title":"Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate","volume":"25","author":"Brown","year":"2014","journal-title":"Osteoporos Int"},{"issue":"6","key":"2024012713535724800_jbmr4157-bib-0039","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","article-title":"Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial","volume":"121","author":"Recknor","year":"2013","journal-title":"Obstet Gynecol."},{"key":"2024012713535724800_jbmr4157-bib-0040","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","article-title":"Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study","volume":"58","author":"Roux","year":"2014","journal-title":"Bone."},{"issue":"1","key":"2024012713535724800_jbmr4157-bib-0041","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J Bone Miner Res."},{"issue":"4","key":"2024012713535724800_jbmr4157-bib-0042","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3349\/ymj.2016.57.4.905","article-title":"Assessment of denosumab in Korean postmenopausal women with osteoporosis: randomized, double-blind, placebo-controlled trial with open-label extension","volume":"57","author":"Koh","year":"2016","journal-title":"Yonsei Med J."},{"issue":"8","key":"2024012713535724800_jbmr4157-bib-0043","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates","volume":"101","author":"Miller","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2024012713535724800_jbmr4157-bib-0044","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00198-011-1786-8","article-title":"Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis","volume":"23","author":"Nakamura","year":"2012","journal-title":"Osteoporos Int."},{"key":"2024012713535724800_jbmr4157-bib-0045","author":"GlaxoSmithKline"},{"issue":"8","key":"2024012713535724800_jbmr4157-bib-0046","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1002\/jbmr.81","article-title":"Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate","volume":"25","author":"Seeman","year":"2010","journal-title":"J Bone Miner Res."},{"key":"2024012713535724800_jbmr4157-bib-0047","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bone.2013.11.016","article-title":"Differing effects of denosumab and alendronate on cortical and trabecular bone","volume":"59","author":"Zebaze","year":"2014","journal-title":"Bone."},{"issue":"3","key":"2024012713535724800_jbmr4157-bib-0048","first-page":"271","article-title":"Treatment of osteoporosis secondary to hypogonadism in prostate cancer patients: a prospective randomized multicenter international study with denosumab vs. alendronate","volume":"69","author":"Doria","year":"2017","journal-title":"Minerva Urol Nefrol."},{"issue":"3","key":"2024012713535724800_jbmr4157-bib-0049","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/pcan.2012.18","article-title":"Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer","volume":"15","author":"Egerdie","year":"2012","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"8","key":"2024012713535724800_jbmr4157-bib-0050","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med."},{"issue":"9810","key":"2024012713535724800_jbmr4157-bib-0051","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet."},{"issue":"30","key":"2024012713535724800_jbmr4157-bib-0052","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9992","key":"2024012713535724800_jbmr4157-bib-0053","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet."},{"issue":"7","key":"2024012713535724800_jbmr4157-bib-0054","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1210\/jc.2013-4175","article-title":"Clinical trials express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT)","volume":"99","author":"Nakamura","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2024012713535724800_jbmr4157-bib-0055","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/jbm4.10054","article-title":"Efficacy of switching from teriparatide to bisphosphonate or denosumab: a prospective, randomized, open-label trial","volume":"2","author":"Niimi","year":"2018","journal-title":"JBMR Plus."},{"issue":"2","key":"2024012713535724800_jbmr4157-bib-0056","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00198-014-2964-2","article-title":"Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)","volume":"26","author":"Sugimoto","year":"2015","journal-title":"Osteoporos Int."},{"issue":"6","key":"2024012713535724800_jbmr4157-bib-0057","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2213-8587(18)30075-5","article-title":"Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study","volume":"6","author":"Saag","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"2024012713535724800_jbmr4157-bib-0058","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/art.23417","article-title":"Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial","volume":"58","author":"Cohen","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"6","key":"2024012713535724800_jbmr4157-bib-0059","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/annrheumdis-2015-208052","article-title":"Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (denosumab) in patients with rheumatoid arthritis on methotrexate to validate inhibitory effect on bone erosion (DRIVE)\u2014a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial","volume":"75","author":"Takeuchi","year":"2016","journal-title":"Ann Rheum Dis."},{"issue":"9","key":"2024012713535724800_jbmr4157-bib-0060","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1210\/jc.2012-1569","article-title":"A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density","volume":"97","author":"Orwoll","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2024012713535724800_jbmr4157-bib-0061","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1007\/s00520-019-04988-7","article-title":"Prospective observational study to evaluate the persistence of treatment with denosumab in patients with bone metastases from solid tumors in routine clinical practice: final analysis","volume":"28","author":"Haslbauer","year":"2020","journal-title":"Support Care Cancer."},{"issue":"6","key":"2024012713535724800_jbmr4157-bib-0062","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00198-020-05379-z","article-title":"Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab","volume":"31","author":"Cummings","year":"2020","journal-title":"Osteoporosis Int"},{"issue":"3","key":"2024012713535724800_jbmr4157-bib-0063","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1034\/j.1399-0004.2003.00036.x","article-title":"The natural history of sclerosteosis","volume":"63","author":"Hamersma","year":"2003","journal-title":"Clin Genet."},{"issue":"1","key":"2024012713535724800_jbmr4157-bib-0064","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00198-011-1546-9","article-title":"Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials","volume":"23","author":"Barrett-Connor","year":"2012","journal-title":"Osteoporos Int."},{"issue":"5","key":"2024012713535724800_jbmr4157-bib-0065","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2005.044958","article-title":"Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study","volume":"65","author":"Reginster","year":"2006","journal-title":"Ann Rheum Dis."},{"issue":"8","key":"2024012713535724800_jbmr4157-bib-0066","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2024012713535724800_jbmr4157-bib-0067","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1742-1241.2010.02335.x","article-title":"Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials","volume":"64","author":"Lewiecki","year":"2010","journal-title":"Int J Clin Pract."},{"issue":"2","key":"2024012713535724800_jbmr4157-bib-0068","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0022-4804(03)00215-4","article-title":"The role of estrogen in cardiovascular disease","volume":"115","author":"Baker","year":"2003","journal-title":"J Surg Res."},{"issue":"11","key":"2024012713535724800_jbmr4157-bib-0069","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1001\/jamainternmed.2019.2779","article-title":"Association between drug treatments for patients with osteoporosis and overall mortality rates: a meta-analysis","volume":"179","author":"Cummings","year":"2019","journal-title":"JAMA Intern Med."},{"issue":"5","key":"2024012713535724800_jbmr4157-bib-0070","doi-asserted-by":"crossref","first-page":"dgz322","DOI":"10.1210\/clinem\/dgz322","article-title":"Risk for infections during treatment with denosumab for osteoporosis: a systematic review and meta-analysis","volume":"105","author":"Diker-Cohen","year":"2020","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.4157","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbmr.4157","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jbmr.4157","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/36\/1\/24\/55459031\/jbmr4157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/36\/1\/24\/55459031\/jbmr4157.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T11:05:50Z","timestamp":1710327950000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/36\/1\/24-40\/7516787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,11]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,8,11]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.4157","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,8,11]]},"assertion":[{"value":"2020-05-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}